On November 14, 2024, Senti Biosciences, Inc., a biotechnology company specializing in cell and gene therapies, announced its financial results for the third quarter ended September 30, 2024. The announcement was made through a press release furnished as Exhibit 99.1 to the company's Form 8-K report filed with the SEC. Senti Biosciences, which trades under the symbol SNTI on the Nasdaq Capital Market, reported a net loss of $28.9 million, or $(6.31) per share, for the quarter. This compares to a net loss of $14.9 million, or $(3.36) per share, for the same period in the previous year. Research and development expenses decreased slightly to $8.7 million from $9.1 million year over year, primarily due to a reduction in headcount, while general and administrative expenses also decreased to $6.2 million from...Show More

On November 14, 2024, Senti Biosciences, Inc., a biotechnology company specializing in cell and gene therapies, announced its financial results for the third quarter ended September 30, 2024. The announcement was made through a press release furnished as Exhibit 99.1 to the company's Form 8-K report filed with the SEC. Senti Biosciences, which trades under the symbol SNTI on the Nasdaq Capital Market, reported a net loss of $28.9 million, or $(6.31) per share, for the quarter. This compares to a net loss of $14.9 million, or $(3.36) per share, for the same period in the previous year. Research and development expenses decreased slightly to $8.7 million from $9.1 million year over year, primarily due to a reduction in headcount, while general and administrative expenses also decreased to $6.2 million from $9.4 million, again attributed to reduced headcount. The company highlighted the ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including Acute Myeloid Leukemia (AML), with initial data expected in Q4 2024. Senti Biosciences also mentioned the receipt of $4.9 million from an $8.0 million grant awarded by the California Institute for Regenerative Medicines (CIRM) and the development of SENTI-301A for solid tumors in collaboration with Celest Therapeutics in China. The company's cash and cash equivalents stood at $10.5 million as of September 30, 2024.